Axial Spondyloarthritis Treatment Market to Grow with a CAGR of 6.70% through 2030
Rise in research and
development activities coupled with increasing public awareness of the disease
to drive the axial spondyloarthritis treatment market in the forecast period,
2026-2030.
According to TechSci Research report, “Axial
Spondyloarthritis Treatment Market - Global Industry Size, Share, Trends, Opportunity,
and Forecast, 2030”, the Global Axial Spondyloarthritis Treatment Market was valued at USD 4.37 billion in 2024 and is expected to reach USD 6.45 billion by 2030 with a CAGR of 6.70% during the forecast period. The increase in incidences of axial spondyloarthritis, and rising technological
advancements are the primary factors driving the demand for the global axial
spondyloarthritis treatment market. Growing public awareness of the disease,
rise in geriatric population, large number of clinical trials, and significant
investment in research and development are expected to influence the market
demand. Also, emphasis of several authorities on improving existing healthcare
infrastructure is also a key factor for increasing the growth of the axial
spondyloarthritis treatment market, globally.
However, the high cost associated with biologics
used to treat axial spondyloarthritis (axSpA), and adverse effects from the
treatment regime may hamper the growth of the global axial spondyloarthritis
treatment market.
Browse over XX market
data Figures spread through XX Pages and an in-depth TOC on "Global Axial Spondyloarthritis Treatment Market"
The global axial
spondyloarthritis treatment market is segmented into therapy, indication, end
user, regional distribution and company.
Based on Indication, Non-radiographic Axial Spondyloarthritis (nr-axSpA) treatment shows the fastest growth in the global axial spondyloarthritis market. Unlike ankylosing spondylitis (AS), where structural damage is already visible on X-rays, nr-axSpA represents an earlier stage of the disease. Over the past decade, awareness and recognition of nr-axSpA have increased significantly due to advances in diagnostic imaging, particularly MRI, which can detect early inflammatory changes before permanent damage occurs. This has led to earlier diagnosis and intervention, fueling demand for effective treatment options. The U.S. Food and Drug Administration (FDA) approval of biologics such as certolizumab pegol and ixekizumab for nr-axSpA has expanded therapeutic choices, accelerating growth in this segment. Similarly, the European Medicines Agency (EMA) has approved multiple biologics for nr-axSpA, reflecting growing clinical acceptance. According to the National Institutes of Health (NIH), approximately 1.4% of the U.S. adult population is affected by axial spondyloarthritis, with nearly half falling into the nr-axSpA category. This indicates a substantial patient pool that is increasingly gaining access to advanced biologic therapies.
Based on the Region, Asia Pacific shows the fastest growth in the global axial spondyloarthritis (axSpA) treatment market. This rapid expansion is attributed to the rising prevalence of autoimmune and inflammatory diseases, increasing healthcare expenditure, and improving access to biologics and targeted therapies across emerging economies. According to the World Health Organization (WHO), the Asia Pacific region accounts for nearly 60% of the world’s population, and with a growing aging demographic, the incidence of chronic rheumatologic disorders, including axSpA, is expected to rise significantly. Countries such as China, India, Japan, and South Korea are witnessing an increase in the diagnosis of spondyloarthritis due to greater awareness, better diagnostic infrastructure, and more rheumatologists entering practice.
Major companies operating
in Global Axial Spondyloarthritis Treatment Market are:
- Novartis AG
- Eli Lilly and Company
- Johnson & Johnson
- UCB S.A.
- Pfizer, Inc.
- Kyowa Kirin Co., Ltd.
- Merck & Co., Inc.
- AbbVie Inc
- Bristol-Myers Squibb Company
- FunPep Co., Ltd.
Download Free Sample Report
Customers can also
request for 10% free customization on this report.
“North America region dominates the
market and is expected to maintain its dominance in the coming years
due to the increased research and development activities. The strongly
established research and healthcare infrastructure, the higher percentage of
total income spent on healthcare, several increasing developmental strategies, rising
awareness among population, favorable reimbursement, and heavy investments by
government in the region is another key factor. Also, owing to numerous biopharmaceutical companies in the region are expected to propel the
global axial spondyloarthritis treatment market growth” said Mr.
Karan Chechi, Research Director of TechSci Research, a research based global
management consulting firm.
“Axial Spondyloarthritis Treatment
Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy (Anti-Tumor Necrosis Factor (TNF) Therapy,
Anti-Interleukin (IL) Therapy, Anti-Janus Kinase (JAK) Therapy), By Indication
(Ankylosing Spondylitis v/s Non-radiographic Axial Spondyloarthritis
Treatment), By End User (Hospitals & Clinics, Academic & Research
Institutions, Others), By Region and Competition, 2020-2030F”, has evaluated the future growth
potential of global axial spondyloarthritis treatment market and provides statistics
& information on market size, structure, and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in global axial spondyloarthritis treatment market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com